|  | Ezetimibe + rosuvastatin (n = 31) |  | Rosuvastatin alone (n = 33) | Difference between groups | ||
---|---|---|---|---|---|---|---|
Liver segment | Baseline | Post-treatment | p-value | Baseline | Post-treatment | p-value | p-value |
I | 16.6 (8.2) | 11.3 (6.4) | < 0.001 | 13.2 (7.3) | 11.5 (7.0) | 0.042 | 0.012 |
II | 16.7 (8.4) | 10.8 (6.0) | < 0.001 | 14.2 (7.4) | 11.8 (7.4) | 0.006 | 0.012 |
III | 17.1 (8.3) | 11.2 (6.6) | < 0.001 | 14.2 (7.6) | 11.9 (7.2) | 0.012 | 0.011 |
IV (A) | 18.0 (8.4) | 12.4 (6.7) | < 0.001 | 15.3 (7.9) | 12.5 (7.5) | 0.004 | 0.038 |
IV (B) | 18.9 (8.8) | 13.4 (7.5) | < 0.001 | 15.9 (7.3) | 13.2 (7.8) | 0.003 | 0.051 |
V | 18.9 (8.7) | 12.9 (6.7) | < 0.001 | 16.1 (7.6) | 13.2 (7.8) | 0.002 | 0.029 |
VI | 18.1 (8.3) | 12.4 (6.7) | < 0.001 | 14.5 (7.5) | 11.7 (7.6) | 0.001 | 0.039 |
VII | 18.6 (7.9) | 12.5 (6.5) | < 0.001 | 15.2 (7.2) | 12.4 (7.3) | 0.001 | 0.018 |
VIII | 19.6 (8.5) | 13.5 (7.2) | < 0.001 | 16.6 (7.4) | 13.6 (7.9) | 0.002 | 0.028 |
MRI-PDFF average, % | 18.1 (8.2) | 12.3 (6.4) | < 0.001 | 15.0 (7.3) | 12.4 (7.4) | 0.003 | 0.020 |
MRE, kPa | 2.0 (0.5) | 2.1 (0.5) | 0.507 | 2.2 (0.4) | 2.2 (0.7) | 0.539 | 0.898 |